Literature DB >> 17709481

Cutting edge: Complement (C3d)-linked antigens break B cell anergy.

Taras Lyubchenko1, Joseph M Dal Porto, V Michael Holers, John C Cambier.   

Abstract

C3dg adducts of Ag can coligate complement receptor type 2 (CR2; CD21) and the B cell Ag receptor. This interaction significantly amplifies BCR-mediated signals in Ag-naive wild-type mice, lowering the threshold for B cell activation and the generation of humoral immune responses as much as 1000-fold. In this study we demonstrate that CR2-mediated complementation of BCR signals can also overcome B cell anergy. Unlike Ag alone, BCR/CR2 costimulation (Ars-CCG/C3dg complexes) of anergic Ars/A1 B cells led to Ca(2+) mobilization in vitro and the production of autoantibodies in vivo. Interestingly, the in vivo immune response of anergic cells occurs without the formation of germinal centers. These results suggest that the Ag unresponsiveness of anergic B cells can be overcome by cross-reactive (self-mimicking) Ags that have been complement-opsonized. This mechanism may place individuals exposed to complement-fixing bacteria at risk for autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709481     DOI: 10.4049/jimmunol.179.5.2695

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy.

Authors:  Cecille D Browne; Christopher J Del Nagro; Matthew H Cato; Hart S Dengler; Robert C Rickert
Journal:  Immunity       Date:  2009-11-05       Impact factor: 31.745

2.  A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice.

Authors:  Yi Hao; Patrick O'Neill; Martin S Naradikian; Jean L Scholz; Michael P Cancro
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

3.  Potentially autoreactive naturally occurring transitional T3 B lymphocytes exhibit a unique signaling profile.

Authors:  Ganna A Liubchenko; Holly C Appleberry; V Michael Holers; Nirmal K Banda; Van C Willis; Taras Lyubchenko
Journal:  J Autoimmun       Date:  2012-02-24       Impact factor: 7.094

4.  Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation.

Authors:  D Saadoun; B Terrier; J Bannock; T Vazquez; C Massad; I Kang; F Joly; M Rosenzwajg; D Sene; P Benech; L Musset; D Klatzmann; E Meffre; P Cacoub
Journal:  Arthritis Rheum       Date:  2013-04

5.  Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes.

Authors:  Ganna A Liubchenko; Holly C Appleberry; Christopher C Striebich; Karen E Franklin; Lezlie A Derber; V Michael Holers; Taras Lyubchenko
Journal:  J Autoimmun       Date:  2012-10-08       Impact factor: 7.094

6.  Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice.

Authors:  Alexandra Francian; Shelby Namen; Madigan Stanley; Kristine Mann; Holly Martinson; Max Kullberg
Journal:  Nanomedicine       Date:  2018-11-09       Impact factor: 5.307

7.  C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro.

Authors:  Pavel A Nikitin; Eileen L Rose; Tony S Byun; Graham C Parry; Sandip Panicker
Journal:  J Immunol       Date:  2019-01-11       Impact factor: 5.422

8.  Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones.

Authors:  Isabelle Isnardi; Yen-Shing Ng; Laurence Menard; Greta Meyers; David Saadoun; Iva Srdanovic; Jonathan Samuels; Jessica Berman; Jane H Buckner; Charlotte Cunningham-Rundles; Eric Meffre
Journal:  Blood       Date:  2010-03-15       Impact factor: 22.113

9.  CD21 signaling via C3 regulates Purkinje cell protein 4 expression.

Authors:  Amanda C Jacobson; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-02-07       Impact factor: 4.407

10.  Antigen-specific suppression of humoral immunity by anergic Ars/A1 B cells.

Authors:  Katja Aviszus; Megan K L Macleod; Greg A Kirchenbaum; Thiago O Detanico; Ryan A Heiser; James B St Clair; Wenzhong Guo; Lawrence J Wysocki
Journal:  J Immunol       Date:  2012-09-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.